Human chorionic gonadotropin (hCG) is a glycoprotein hormone that plays a crucial role in the establishment and maintenance of pregnancy. Its early production by the developing embryo and subsequent secretion by the placenta make it a vital signal for the continuation of pregnancy. hCG influences a range of physiological processes, including trophoblast differentiation, angiogenesis, and immune modulation, which are essential for successful placentation.
Related Products
Molecular Structure and Variants of hCG
hCG is composed of two subunits: alpha (α) and beta (β), which are linked non-covalently. The α-subunit is common to other glycoprotein hormones like luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). The β-subunit is unique to hCG and determines its specific biological activities. There are several variants of hCG, including regular hCG, hyperglycosylated hCG (hhCG), and the free β-subunit of hCG, each playing distinct roles in pregnancy.
Fig. 1 Structure of hCG at 2.6 angstrom resolution (d'Hauterive S. P., et al. 2022).
Regular hCG: Regular hCG is primarily responsible for maintaining the corpus luteum in early pregnancy, ensuring the continued production of progesterone, which is crucial for sustaining the uterine lining and creating a suitable environment for the developing embryo.
Hyperglycosylated hCG (hhCG): hhCG is produced by the invasive cytotrophoblast cells of the placenta and is essential during early placentation. Its primary role is to support the invasion of trophoblast cells into the uterine wall, a critical process for establishing a robust placenta.
Free β-Subunit of hCG: The free β-subunit is a non-functional variant often associated with trophoblastic diseases and certain cancers. Its measurement can be useful in diagnosing these conditions.
Early Production and Function of hCG
hCG is one of the earliest signals from the embryo to the mother, detectable as early as eight days post-fertilization. It supports the corpus luteum, ensuring the continued production of progesterone, which is essential for maintaining the uterine lining and providing a suitable environment for the developing embryo. The exponential rise in hCG levels during the first trimester correlates with the rapid growth and development of the placenta.
hCG and Angiogenesis
Angiogenesis, the formation of new blood vessels, is critical for placental development and function. hCG acts as a potent angiogenic factor, promoting the proliferation, migration, and differentiation of endothelial cells. Studies have shown that hCG enhances capillary formation and induces neovascularization in various experimental models, including the chicken chorioallantoic membrane and human placental microvascular endothelial cells. These effects are mediated through the activation of the LH/hCG receptor (LH/hCG-R) and downstream signaling pathways involving AMP/protein kinase A (PKA) and transforming growth factor-beta (TGF-β) receptor complexes.
hCG and Immune Modulation
Successful pregnancy requires maternal immune tolerance towards the semi-allogenic fetus. hCG plays a pivotal role in modulating the maternal immune system to prevent fetal rejection. It promotes the production of regulatory T cells (Tregs), which are crucial for maintaining immune tolerance. Additionally, hCG downregulates pro-inflammatory cytokines and upregulates anti-inflammatory cytokines, creating an immune environment conducive to fetal development.
Interaction with Heme Oxygenase-1 (HO-1)
HO-1 is an inducible enzyme that catalyzes the degradation of heme to biliverdin, carbon monoxide (CO), and ferrous iron. It has cytoprotective, anti-inflammatory, and anti-oxidative properties, making it vital for placental function. Interestingly, hCG and HO-1 are functionally interlinked in pregnancy. hCG upregulates HO-1 expression, contributing to the regulation of trophoblast invasion and placental angiogenesis. HO-1, in turn, modulates the production of angiogenic factors like vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), enhancing placental vascularization and function.
hCG and Preeclampsia
Preeclampsia is a severe pregnancy-related disorder characterized by hypertension and proteinuria after 20 weeks of gestation. It is associated with abnormal placentation and endothelial dysfunction. Low levels of hCG and HO-1 expression have been implicated in the pathogenesis of preeclampsia. The interplay between hCG and HO-1 in regulating trophoblast invasion and angiogenesis is crucial for placental development. Reduced expression of these factors can lead to impaired placental perfusion, contributing to the clinical manifestations of preeclampsia.
Genetic Variability and Susceptibility
Genetic polymorphisms in the HO-1 gene (HMOX1) affect its expression and activity. The (GT)n repeat polymorphism in the promoter region of HMOX1 influences its transcriptional activity, with longer repeats (L-type) associated with lower HO-1 expression. Studies have shown that individuals carrying the L-type allele have an increased susceptibility to preeclampsia. The interaction between hCG and HO-1 in individuals with different HMOX1 genotypes may influence the risk and severity of preeclampsia, highlighting the importance of genetic factors in pregnancy outcomes.
Clinical Applications of hCG
The measurement of hCG levels is a standard practice in the diagnosis and monitoring of pregnancy. It is also used in clinical settings to induce ovulation and support early pregnancy in assisted reproductive technologies (ART). Moreover, hCG has potential therapeutic applications in conditions like recurrent pregnancy loss and preeclampsia, where enhancing its levels or mimicking its effects could improve pregnancy outcomes.
hCG as a Biomarker
hCG levels are routinely measured to confirm pregnancy, monitor its progression, and diagnose potential complications like ectopic pregnancy and trophoblastic diseases. Abnormally low or high hCG levels can indicate underlying issues that require medical intervention. Additionally, hCG is used as a marker for certain types of cancer, including choriocarcinoma and testicular cancer.
Therapeutic Potential
The therapeutic use of hCG extends beyond its role in pregnancy. In ART, hCG is administered to trigger final oocyte maturation and ovulation. Its immunomodulatory and angiogenic properties make it a potential candidate for treating pregnancy-related disorders. For instance, hCG administration could potentially improve outcomes in patients with recurrent pregnancy loss or preeclampsia by enhancing placental development and function.
Conclusion
Human chorionic gonadotropin (hCG) is a multifunctional hormone that plays a central role in the establishment and maintenance of pregnancy. Its interactions with HO-1 and other key molecules are critical for successful placentation, immune tolerance, and vascular development. Understanding these interactions and the underlying genetic factors influencing hCG and HO-1 function can provide valuable insights into pregnancy-related disorders and lead to novel therapeutic approaches. As research continues to unravel the complexities of hCG's role in pregnancy, its potential for improving maternal and fetal health becomes increasingly evident. The exploration of hCG variants and the application of personalized medicine approaches hold promise for advancing reproductive health and enhancing pregnancy outcomes.
References
- Montagnana M., et al. Human chorionic gonadotropin in pregnancy diagnostics. Clinica Chimica Acta. 2011, 412 (17-18): 1515-20.
- d'Hauterive S. P., et al. Human chorionic gonadotropin and early embryogenesis. International Journal of Molecular Sciences. 2022, 23 (3): 1380.
.
